EUDA Health Holdings Ltd
corporate_fare Company Profile
EUDA Health Holdings Ltd (NASDAQ:EUDA) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 21 items for EUDA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-07-28, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for EUDA spans 6-K, F-3, 20-F, 424B5.
Recent high-impact activity:
- EUDA Health Enters Tri-Party MOU for Next-Generation iPSC and NK-TCR Cell Therapies
- EUDA Health Inks Tri-Party MOU to Develop Next-Gen iPSC and NK-TCR Cell Therapies
- EUDA Health Terminates $10M At-The-Market Offering, Removing Dilution Overhang
- EUDA Health Launches Regenixé iPSC-Derived Skin Stem Cell Secretome Mask, Expanding Helixé Product Line
- EUDA Health Regains Nasdaq Compliance, Resolving Delisting Threat
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for EUDA, detected from its recent SEC filings · based on capital-structure filings through 2026-08-11.
ATM Offering Terminated · Potential Dilution Removed
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
EUDA files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.